A Phase 3 interventional study of tapinarof cream, 1% and vehicle cream in Atopic Dermatitis, sponsored by Organon and Co. Completed at 62 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.
Sponsored by Organon and Co · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing tapinarof in Dermatitis, Atopic — 1 open to participants now, 2 under way, 1 of them phase 3. tapinarof · Dermatitis, Atopic.
Among the 12 studies testing tapinarof in Dermatitis, Atopic, this one is the 3rd largest by enrollment, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 7th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →1 of the 12 studies testing tapinarof in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 5 · Phase 4 1
First in 2008; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 406 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 168 across the 12 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 12 have an industry lead sponsor. The 5 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
14 studies in Dermatitis, Atopic by Organon & Co.: none open now, 1 under way, 1 of them phase 3. Of 12 finished, 6 (50%) have results posted.
Among the 14 studies in Dermatitis, Atopic by Organon & Co., this one is the 3rd largest by enrollment, is one of 4 that started in 2021, is one of 6 in phase 3, and was the 11th registered.
Organon & Co.’s Dermatitis, Atopic studies by the year they started, since 2003.
1 of the studies testing tapinarof in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing tapinarof in Dermatitis, Atopic, from their registry updates:
Among Organon & Co.’s 14 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.
This study is a 8-week double-blind, vehicle-controlled treatment study in which subjects will be randomized to receive tapinarof cream, 1% or vehicle cream once daily for 8 weeks. At the end of the 8-week study treatment, qualified subjects will have the option to enroll in an open-label, long-term extension study for an additional 48 weeks of treatment. Subjects who do not participate in the open-label, long-term extension study will complete a follow-up visit approximately one week after the end of treatment in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
tapinarof cream, 1%, applied topically once daily
Drug: tapinarof cream, 1%
vehicle cream, applied topically once daily
Drug: vehicle cream
applied topically once daily
applied topically once daily
Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.
The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. Statistics are based on 100 imputed datasets.
Time frame: Baseline to Week 8
Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.
The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. Statistics are based on 100 imputed datasets.
Time frame: Baseline to Week 8
Mean Change in in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 8.
Assessment of percent body surface area (%BSA) is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% \[10 handprints\], upper extremities = 20% \[20 handprints\], trunk (including axillae and groin) = 30% \[30 handprints\], lower extremities, including buttocks, = 40% \[40 handprints\]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.
Time frame: Baseline to Week 8
Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.
The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. Statistics are based on 100 imputed datasets.
Time frame: Baseline to Week 8
Percent of Subjects ≥ 12 Years Old With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the Average Weekly PP-NRS From Baseline to Week 8.
The Peak Pruritus Numeric Rating Scale (PP-NRS) is used to quickly assess itch/pruritus severity over a 24-hour period. The PP-NRS is scored on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable". The subject will utilize the scale to assess peak pruritis once per day and record the results in their diaries. The daily ratings are averaged to generate a score for the week. Statistics are based on 100 imputed datasets.
Time frame: Baseline to Week 8
Participants from the main study (DMVT-505-3102) had the option to participate in the open label extension study (DMVT-505-3103, NCT05142774).
| Milestone | Tapinarof Cream | Vehicle Cream |
|---|---|---|
| Started | 271 | 135 |
| Completed | 235 | 106 |
| Not completed | 36 | 29 |
The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. Statistics are based on 100 imputed datasets.
| Percentage of participants | Tapinarof Cream | Vehicle Cream |
|---|---|---|
| Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. | 46.4 | 18.0 |
The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. Statistics are based on 100 imputed datasets.
| Percentage of participants | Tapinarof Cream | Vehicle Cream |
|---|---|---|
| Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. | 59.1 | 21.2 |
Assessment of percent body surface area (%BSA) is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% \[10 handprints\], upper extremities = 20% \[20 handprints\], trunk (including axillae and groin) = 30% \[30 handprints\], lower extremities, including buttocks, = 40% \[40 handprints\]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.
| Change in affected BSA percentage | Tapinarof Cream | Vehicle Cream |
|---|---|---|
| Mean Change in in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 8. | -10.36 ± 0.540 | -3.14 ± 0.676 |
The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. Statistics are based on 100 imputed datasets.
| Percentage of participants | Tapinarof Cream | Vehicle Cream |
|---|---|---|
| Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation. | 30.1 | 10.0 |
The Peak Pruritus Numeric Rating Scale (PP-NRS) is used to quickly assess itch/pruritus severity over a 24-hour period. The PP-NRS is scored on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable". The subject will utilize the scale to assess peak pruritis once per day and record the results in their diaries. The daily ratings are averaged to generate a score for the week. Statistics are based on 100 imputed datasets.
| Percentage of participants | Tapinarof Cream | Vehicle Cream |
|---|---|---|
| Percent of Subjects ≥ 12 Years Old With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the Average Weekly PP-NRS From Baseline to Week 8. | 52.8 | 24.1 |
Collected over Through study completion, up to 9 weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tapinarof Cream | 0/271 (0%) | 2/271 (0.7%) | 55/271 (20.3%) |
| Vehicle Cream | 0/133 (0%) | 0/133 (0%) | 13/133 (9.8%) |
| Event | Tapinarof Cream | Vehicle Cream |
|---|---|---|
| Colitis ischaemicGastrointestinal disorders | 1/271 | 0/133 |
| Psychogenic seizureNervous system disorders | 1/271 | 0/133 |
| Event | Tapinarof Cream | Vehicle Cream |
|---|---|---|
| FolliculitisInfections and infestations | 22/271 | 2/133 |
| Upper respiratory tract infectionInfections and infestations | 8/271 | 2/133 |
| COVID-19Infections and infestations | 6/271 | 0/133 |
| PyrexiaGastrointestinal disorders | 4/271 | 2/133 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 3/271 | 2/133 |
| EczemaSkin and subcutaneous tissue disorders | 1/271 | 2/133 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/271 | 2/133 |
| NasopharyngitisInfections and infestations | 4/271 | 1/133 |
| HeadacheNervous system disorders | 4/271 | 0/133 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 4/271 | 0/133 |
ITT Population
| Age, Continuous(years) | Tapinarof Cream | Vehicle Cream | Total |
|---|---|---|---|
| Mean | 16.4 ± 16.24 | 16.7 ± 16.05 | 16.5 ± 16.16 |
| Age, Customized(Participants) | Tapinarof Cream | Vehicle Cream | Total |
|---|---|---|---|
| 2-6 Years | 65 | 32 | 97 |
| 7-11 Years | 64 | 32 | 96 |
| 12-17 Years | 89 | 44 | 133 |
| ≥18 Years | 53 | 27 | 80 |
| Sex: Female, Male(Participants) | Tapinarof Cream | Vehicle Cream | Total |
|---|---|---|---|
| Female | 154 | 77 | 231 |
| Male | 117 | 58 | 175 |
| Ethnicity (NIH/OMB)(Participants) | Tapinarof Cream | Vehicle Cream | Total |
|---|---|---|---|
| Hispanic or Latino | 49 | 27 | 76 |
| Not Hispanic or Latino | 221 | 107 | 328 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Tapinarof Cream | Vehicle Cream | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 2 |
| Asian | 39 | 23 | 62 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 95 | 47 | 142 |
| White | 124 | 58 | 182 |
| More than one race | 6 | 2 | 8 |
| Unknown or Not Reported | 6 | 3 | 9 |
| Region of Enrollment(Count of participants) | Tapinarof Cream | Vehicle Cream | Total |
|---|---|---|---|
| Canada | 41 | 22 | 63 |
| United States | 230 | 113 | 343 |
| Validated Investigator Global Assessment for Atopic Dermatitis(Participants) | Tapinarof Cream | Vehicle Cream | Total |
|---|---|---|---|
| 0 - Clear | 0 | 0 | 0 |
| 1 - Almost Clear | 0 | 0 | 0 |
| 2 - Mild | 0 | 0 | 0 |
| 3 - Moderate | 228 | 113 | 341 |
| 4 - Severe | 43 | 22 | 65 |
| Percent Body Surface Area (BSA)(Percentage of Affected BSA) | Tapinarof Cream | Vehicle Cream | Total |
|---|---|---|---|
| Mean | 17.13 ± 8.743 | 15.84 ± 7.888 | 16.70 ± 8.480 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in Feb 2023, 16 months.
Results were first posted in Sep 2025, 2 years 6 months after primary completion. A results delay was requested in Mar 2023.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 16 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tapinarof